Home' Australian Pharmacist : Australian Pharmacist June 2014 Contents Australian Pharmacist June 2014 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
Submit your answers online before
1 August 2014 at www.psa.org.au and
receive automatic feedback, or NZ
members can fax/mail to:
NZCP CPD answers,
PO Box 11 640, Wellington
F: 04 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD & PI program. It is also part of the New
Zealand College of Pharmacists (NZCP) education
program for NZ pharmacists.
The CPD section is recognised under the PSA
CPD & PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions,
4 out of 5 questions, or 3 out of 4 questions
correct is required for the allocation of Group 2
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your
answers online. If you do not have member
access details, you can request them via a
link from the login page.
• Select Pharmacist Members from the blue,
left hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
1. Which of the following DDP-4
inhibitors does not require dose
reduction in renal impairment?
2. After what period of time should the
dose of exenatide be increased from
5 mcg twice daily to 10 mcg twice
a) 1 week.
b) 3 days.
c) 4 weeks.
d) 5 days.
3. Which of the following statements is
incorrect in regards to therapy with
a) The relationship between pancreatic
adverse effects and the use of GLP-1
analogues has been firmly established.
b) Patients taking GLP-1 agonists may see a
small reduction in weight e.g. 3kg at the
beginning of therapy.
c) The use of exenatide is contraindicated
in patients where estimated creatinine
clearance is less than 30 mL/minute.
d) Patients who forget to administer
exenatide before a meal should
wait until their next scheduled dose
before administering again (i.e. do not
administer a catch-up dose).
4. Which of the following statements is
incorrect in regards to therapy with
a) DDP-4 inhibitors may increase the risk
b) The reduction in HbA1C
different between different DDP-4
c) The usual dose of vildagliptin is 50 mg
once or twice daily.
d) There does not appear to be any
significant effect on weight with the use
of DDP-4 inhibitors.
5. Which of the following is correct?
a) Liraglutide is administered twice daily.
b) DDP-4 inhibitors prolong the effects
of substance P, potentially leading to
c) Gastric emptying is increased with the
use of GLP-1 agonists.
d) Exenatide may be supplied as a
PBS-subsidised medicines in patients
1. Montanya E. A comparison of currently available GLP-1
receptor agonists for the treatment of type 2 diabetes.
Expert Opin Pharmacother. 2012;13(10):1451–67.
2. How common is diabetes? Australian Institute of Health
and Welfare; 2013 [cited 2014 April]; At: www.aihw.gov.au/
3. Therapeutic Guidelines: Introduction to
antihyperglycaemic therapy in type 2 diabetes [CD].
Melbourne: Therapeutic Guidelines; 2013.
4. Prins JB. Incretin mimetics and enhancers: mechanism of
action. Aust Prescr. 2008;31:102–4 .
5. Dungan K. Glucagon-like peptide-1 based therapies for
the treatment of type 2 diabetes mellitus. Up To Date;
2014 [cited 2014 April]; At: www.uptodate.com/contents/
6. Therapeutic Guidelines: Incretin-based therapies in type 2
diabetes [CD]. Melbourne: Therapeutic Guidelines; 2014.
7. Assessment report for GLP-1 based therapies. European
Medicines Agency; 2013 [cited 2014 Aprl]; At: www.
8. Cerena S, Raz I. Therapy in the early stage: Incretins.
Diabetes Care. 2011;34(Suppl 2):S264–S71.
9. Cobble M. Differentiating among incretin-based therapies
in the management of patients with type 2 diabetes
mellitus. Diabetology & Metabolic Syndrome. 2012;4(8).
10. In Brief. NPS Radar.Aug 2010:20-4 .
11. Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S.
Incretin-based therapies: viewpoints on the way to
consensus. Diabetes Care. 2009;32(Suppl 2):S223–S31.
12. Product information liraglutide Victoza. Novo Nordisk
Pharmaceuticals; 2012 [cited 2014 Apr]; At: www.
13. Australian Medicines Handbook: Glucagon-like peptide-1
analogues. Adelaide: Australian Medicines Handbook;
2014 [cited 2014 Apr].
14. Exenatide. Australian Government Department of
Health; [cited 2014 Apr]; At: http://pbs.gov.au/medicine/
15. Drucker DJ, Nauck MA. The incretin system: glucagon-like
peptide-1 receptor agonists and dipeptidyl peptidase-4
inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.
16. eMIMS: Prescribing Information: Byetta. St Leonards, NSW:
MediMedia Australia; 2013 [cited 2014 Apr].
17. eMIMS: Prescribing Information: Victoza®. St Leonards,
NSW: MediMedia Australia; 2013 [cited 2014 Apr].
18. Garber A. Long-acting glucagon-like peptide 1 receptor
agonists. Diabetes Care. 2011;34(Suppl 2):s279–84.
19. Gale EAM. GLP-1 based agents and acute pancreatitis.
20. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith
A. Glucagon-like peptide analogues for type 2 diabetes
mellitus. Cochrane Database os Systematic Reviews.
2011(10):Art. No.: CD006423.
21. Dipeptidyl peptidase-4 inhibitors (‘gliptins’) for type 2
diabetes mellitus. NPS Radar.August 2010:1-6 .
22. Sitagliptin phosphate, tablets, 100 mg, 50 mg and 25 mg,
Januvia, Mar 2008. Australian Government Department
of Health; 2008 [cited 2014 Apr]. At: www.health.gov.au/
23. Sitagliptin. Australian Government Department of Health;
[cited 2014 Apr]; At: http://pbs.gov.au/medicine/item/9180e-
24. Australian Medicines Handbook: Dipeptidyl peptidase-4
inhibitors. Adelaide: Australian Medicines Handbook; 2014
[cited 2014 Apr].
25. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4
inhibitors for the treatment of type 2 diabetes mellitus.
26. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk
of acute pancreatitis and biliary disease observed in patients
with type 2 diabetes. Diabetes Care. 2009;32(5):834–8 .
27. Singh S, Chang H, Richards TM, Weiner JP, Clark JM, Segal
JB. Glucagonlike peptide 1-based therapies and risk of
hospitalisation for acute pancreatitis in type 2 diabetes
mellitus. JAMA Intern Med. 2013;173(7):534–9 .
28. Garg R, Chen W, Pendengrass M. Acute pancreatitis in type 2
diabetes treated with exenatide or sitagliptin – a retrospective
observational pharmacy claims analysis. Diabetes Care.
29. eMIMS: Prescribing Information: Trajenta. St Leonards, NSW:
MediMedia Australia; 2013 [cited 2014 Apr]
Links Archive Australian Pharmacist May 2014 Australian Pharmacist July 2014 Navigation Previous Page Next Page